Peter Sazani

This inventor holds 8 USPTO granted patents and 8 published patent applications and 5 EPO patents. Top assignees: Sarepta Therapeutics, Inc., Avi Biopharma, Inc.. Active years: 2011-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Sazani. Retrieved from https://idiyas.com/inventor/peter-sazani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 8)

% Patents Active = 87.5

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 2.1

ph-index = 7

Forward Citations = 349(Granted Patents)

Location History:

Corvallis, OR (US) (2011)
Bothell, WA (US) (2014 - 2016)

Company Filing History:

7 out of 127

Sarepta Therapeutics, Inc.

Years Active: 2011-2016

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9453225 - Multiple exon skipping compositions for DMD (2016-09-27),

2. 9447417 - Multiple exon skipping compositions for DMD (2016-09-20),

3. 9447416 - Multiple exon skipping compositions for DMD (2016-09-20),

4. 9434948 - Multiple exon skipping compositions for DMD (2016-09-06),

5. 9234198 - Multiple exon skipping compositions for DMD (2016-01-12),

6. 8871918 - Multiple exon skipping compositions for DMD (2014-10-28),

7. 8865883 - Multiple exon skipping compositions for DMD (2014-10-21),

8. 7884194 - Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease (2011-02-08),

Title: The Inventive Journey of Peter Sazani

Introduction

Peter Sazani, a talented inventor based in Bothell, WA (US), has made significant contributions to the field of biotechnology through his innovative work. With a total of 8 patents to his name, Sazani has focused on developing novel therapies for muscular dystrophy, particularly in the area of exon skipping treatments.

Latest Patents

Among his latest patents is the groundbreaking invention titled "Multiple exon skipping compositions for DMD." These antisense molecules are designed to bind to specific target sites in the human dystrophin gene, inducing exon skipping. This innovative approach shows promise in the treatment of muscular dystrophy, offering hope to patients and their families.

Career Highlights

Sazani has garnered valuable experience working in renowned companies such as Sarepta Therapeutics, Inc. and Avi Biopharma, Inc. His expertise and dedication to research have been instrumental in advancing the development of cutting-edge therapies for genetic disorders.

Collaborations

Throughout his career, Sazani has collaborated with esteemed professionals in the field, including Ryszard M Kole and Jing Wan. These collaborations have fostered a creative environment where ideas flourish, leading to the successful execution of innovative projects.

Conclusion

In conclusion, Peter Sazani's unwavering commitment to innovation and his pioneering work in the field of biotechnology have positioned him as a key figure in the quest for effective treatments for muscular dystrophy. His patents and collaborations stand as a testament to his remarkable contributions to the scientific community and the lives of those affected by genetic disorders.

Profile summary based on public USPTO records.